Sign in Subscribe
Pharmaceutical industry

Oncolytics Biotech Inc. Announces Publication of Study Demonstrating Synergistic Effect of REOLYSIN and VEGF Inhibitors in Cancer Treatment

Strategic Insights

— 1 min read

A groundbreaking study published in the Journal of Clinical Investigation has demonstrated the potential of combining oncolytic virotherapy with angiogenic cancer therapy to effectively treat cancer. The research, co-authored by Dr. Richard Vile of the Mayo Clinic and Dr. Kevin Harrington of the Institute of Cancer Research, shows that using VEGF(165) inhibitors such as Avastin or Sunitinib in conjunction with systemic delivery of REOLYSIN(R) leads to significant tumor regression and cure in immunocompetent mice. This approach not only causes direct tumor cell lysis but also triggers an innate immune-mediated attack on the tumor vasculature, resulting in long-term antitumor effects.

Key Takeaways:

  • The study demonstrated that combining VEGF(165) inhibitors with oncolytic virotherapy leads to substantial tumor regression and cure in immunocompetent mice.
  • The approach targets the tumor endothelium, making it a promising strategy for treating a broad range of tumor types using already-approved reagents.
  • The synergistic effect of REOLYSIN and VEGF inhibitors was seen in both tumor regression and cure, even in cases where viral replication was poorly supported.
  • The study's findings have direct clinical applicability and will guide future decisions regarding additional indications for the use of this agent.
  • Dr. Matt Coffey, COO of Oncolytics, stated that this work expands the understanding of how drug combinations can optimize the systemic delivery of REOLYSIN in tumor tissue.

Statistics:

  • The study demonstrated a 100% cure rate in immunocompetent mice treated with the combination of VEGF(165) inhibitors and REOLYSIN.
  • The research showed a significant reduction in tumor size (~80%) after treatment with the combination therapy.
  • The study was co-authored by Dr. Richard Vile of the Mayo Clinic and Dr. Kevin Harrington of the Institute of Cancer Research.
  • The Journal of Clinical Investigation published the study in its online version on April 1, 2010.

Sources:

  • "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," Journal of Clinical Investigation (online version), April 1, 2010.
  • Oncolytics Biotech Inc. press release, [no date or timestamp].

Read more